top of page

Cutting Edge Technology

Author, and entrepreneur, Ketan Desai receives recognition for a breakthrough in pain management therapy.

"The development of a disease modifying drug for osteoarthritis has been an unachievable quest so far, but with VOLT01, that goal may finally be achieved," said Inventor and Levolta Chief Medical Officer, Ketan Desai, M.D., Ph.D. "Our Phase II studies demonstrate long lasting pain relief, up to 9 months, in patients with osteoarthritis after a single 30-minute intravenous infusion. More importantly, VOLT01 showed disease modifying activity as measured by MRI with pain relief correlating with disease modification. We look forward to pivotal studies that will enable VOLT01 to have a label for pain relief of osteoarthritis in all joints along with disease modification after a single yearly infusion.

To read more about this, click here.

5 views0 comments


bottom of page